Micromedex vs Lexicomp (Lexidrug) cost, IV compatibility and which drug database your pharmacy needs

This is where the two vendors behave completely differently, and it is the most useful thing a buyer takes away from the comparison. Wolters Kluwer publishes a number you can read without talking to anyone: Apple's US App Store lists the personal UpToDate Lexidrug subscription at $29.99 a month, and new individual users get a one-month trial of the Hospital Pharmacist package that then renews at that rate, with cancellation required at least 24 hours before the trial ends. Across a year that is roughly $360, and there is no free tier.

Merative publishes nothing. We checked the Micromedex product and pricing pages again in September 2026 and there is no dollar figure anywhere on them, at any tier. Micromedex is quoted per organization on user count, modules and contract term, and there is no realistic path for an individual clinician to buy it the way they can buy Lexidrug. You will find confident monthly and annual figures for both products on software directory sites. Those numbers are not vendor-published, they contradict each other, and we do not repeat them. Our fuller breakdowns are in Micromedex subscription cost and Lexicomp subscription cost.

Public purchasing records fill the gap Merative leaves. Federal awards on USAspending.gov put a single VA medical center at $4,780.75 for one year of Micromedex, a Defense Health Agency NeoFax and pediatric package at $5,979, and a premium Clinical Evidence package at $19,160 for its base year. Adding RED BOOK drug pricing data took one Government Accountability Office subscription to $40,312.50 for a year. Those are prices for a whole site, not a pharmacist, and every award is listed on our Micromedex subscription cost page.

The pattern is worth naming because it repeats across this whole category: transparency tracks who the buyer is, not how good the product is. Anything sold to a clinician with a credit card carries a published price. Anything sold to a procurement department does not. That is why Lexidrug shows a number and Micromedex does not, and it says nothing about which database is better. The purest case is UpToDate versus Micromedex, where both are procurement products and neither vendor publishes a figure at any tier.

Both compendia ship an interaction checker, and the difference is in the rating scale and the scope. Micromedex Drug Interactions grades each pair by severity (contraindicated, major, moderate, minor) and separately by the quality of documentation (excellent, good, fair, poor), and it screens drug-drug pairs including herbals plus drug-food, drug-ethanol, drug-lab, drug-tobacco, pregnancy, lactation and ingredient duplication. Lexi-Interact, the Lexicomp checker, rates pairs on its A, B, C, D and X scale, where X means avoid the combination, and covers drug-drug, drug-allergy, duplicate therapy and herbal products.

In practice a pharmacist who reads the documentation grade will prefer Micromedex for contested pairs, and a prescriber who wants a one-letter action will find the Lexicomp scale faster. The access rule is the same as for the rest of each product: Micromedex interactions come with the hospital license, while Lexi-Interact is inside the $29.99-a-month Lexidrug app. Our Lexicomp drug interaction checker guide walks through the ratings, and neither checker looks at the patient's conditions or kidney function, which is the gap our drug contraindication checker fills.

Micromedex is the name most pharmacists give first, and Merative supports that positioning by selling IV compatibility tools as a distinct offering within the Micromedex family rather than folding it silently into the main database. If your team prepares or administers intravenous medications daily, this single workflow is often what decides the contract, because a compatibility question at the bedside cannot wait for a second lookup somewhere else.

Lexidrug carries compatibility content too, but whether you can reach it depends on which package your institution licensed, since Wolters Kluwer sells compatibility content as part of specific configurations rather than including it everywhere. That makes the evaluation concrete rather than theoretical. Take three drug pairs your team actually questions, search each one inside both trials, and see which returns a usable answer in your own subscription. Vendor feature lists will not settle this; your own test will.

One thing to be clear about: this is a gap on our side, not a strength. Prescriber.io does not carry IV compatibility data and is not built to answer that question. If IV compatibility is the reason you are buying, buy the compendium that answers it.

DRUGDEX is a long-standing content set name that many institutions, library guides and citation styles still use, and a lot of pharmacists learned the database under that name. It is not a separate competing product. What we can verify today is narrower than what older documentation suggests: Merative's current Micromedex pages present Micromedex as the drug database and do not foreground the DRUGDEX name, and the clinical decision support family is listed as Micromedex, DynaMedex and OrbitalRX with Micromedex.

The practical advice is to stop reasoning from module names you remember and check your own entitlement. Content set names in this category change more often than the content does, and the question that actually matters at renewal is which sets your license includes, not what they were called when you trained. Ask the vendor to list the included content sets in writing on the quote.

Some large systems do, but most pick one. Where both exist it is usually for one of two reasons: different departments made separate purchasing decisions and nobody consolidated them, or a specific compatibility, toxicology or neonatal need justified a second contract on clinical grounds. Duplicating a full compendium is expensive and hard to defend when the renewal comes up, so it tends to be the first thing a pharmacy director is asked about in a cost review.

If you are the one being asked to justify it, the defensible version of the answer is workflow-specific rather than general. "We keep Micromedex because our IV room queries it fifteen times a shift and Lexidrug does not answer those in our package" is a case. "Both are good references" is not. Pull the actual usage statistics from each vendor before the meeting, because in most systems one of the two is being used a fraction as much as the other and nobody has looked.

The wider licensing question, including the user-count thresholds that push you from individual to enterprise contracts, is covered in our guide to institutional and group licensing.

Both are tertiary sources, and so is UpToDate. Primary sources are the original studies. Secondary sources are the indexes that help you find them, such as PubMed or Embase. Tertiary sources are the compendia and databases that compile and interpret the primary literature into something you can use in thirty seconds. Merative describes Micromedex as curated from primary literature under an accredited editorial process with in-line referencing, which is a precise description of what a tertiary source does.

This matters when you are writing a drug information response or defending a formulary decision, because the expectation in those settings is that you trace a claim back through the compendium to the study rather than cite the compendium as the last word. Both products support that, since both reference the literature they are built from. Use them to find and frame the answer fast, then follow the citation when the stakes or the audience require the original. We work through the full hierarchy, including how to cite a continuously updated database, in is Micromedex a tertiary source.

Both databases are excellent at answering a question you have already thought to ask. Neither one watches the order in front of you and volunteers, unprompted, that this patient is already on something that interacts with it, that their kidney function makes the standard dose wrong, or that a documented allergy rules out the obvious first choice. Getting all of that from a compendium means knowing to run several separate lookups in a row, and prescribing errors cluster precisely where nobody thought to look.

That is the narrow job Prescriber.io is built for. You enter the drug or the scenario once and it checks for drug-drug interactions, flags contraindications and allergy blockers, surfaces renal and hepatic dose adjustments, and suggests guideline-based alternatives, together, with a cited source on each flag so you can confirm it. It is decision-support, not autonomous prescribing: every flag is a prompt for a licensed clinician who reviews it, verifies against official sources, and signs. If you are weighing whether a compendium still earns its line item, our Lexicomp alternative and Micromedex alternative pages cover that, the role-by-role picture is in our guide to the best drug reference apps, and the wider field is laid out in our guide to the best clinical decision support software.